HUTCHMED announced that new and updated preclinical and clinical data for its drug candidates HMPL-A580 and surufatinib will be presented at the AACR Annual Meeting 2026 in April.
Key takeaways
Preclinical data for HMPL-A580, a first-in-class PI3K/PIKK-EGFR Antibody-Targeted Therapy Conjugate, will be presented, showing potent inhibition and selectivity in preclinical models.
Updated results from a Phase Ib/II trial of surufatinib plus sintilimab and capecitabine in previously treated metastatic small bowel adenocarcinoma and appendiceal carcinoma will be presented.
Results from an exploratory Phase II study of surufatinib combined with gemcitabine and nab-paclitaxel for pancreatic ductal adenocarcinoma will be presented.
HUTCHMED plans to apply its partnership strategy to its ATTC technology this year to accelerate development.
HMPL-A580 is the second ATTC candidate based on a novel PI3K/PIKK inhibitor payload linked to an anti-EGFR antibody.